Bone-targeted methotrexate–alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo

References

• Abe Y, Iba K, Sasaki K, et al. (2015). Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice. J Bone Miner Metab 33:125–34.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. (2004). Drug delivery systems: entering the mainstream. Science 303:1818–22.
   PubMed Web of Science ®Google Scholar
• Asagiri M, Hirai T, Kunigami T, et al. (2008). Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 319:624–7.
   PubMed Web of Science ®Google Scholar
• Chan AJ, Rajakumar I. (2014). High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity. J Oncol Pharm Pract 20:93–9.
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS. (2001). Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–16.
   PubMed Web of Science ®Google Scholar
• Cronstein BN. (2005). Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163–72.
   PubMed Web of Science ®Google Scholar
• Fazil M, Baboota S, Sahni JK, et al. (2015). Bisphosphonates: therapeutics potential and recent advances in drug delivery. Drug Deliv 22:1–9.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini SR. (2008). Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 223:7–19.
   PubMed Web of Science ®Google Scholar
• Finckh A, Simard JF, Duryea J, et al. (2006). The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum 54:54–9.
   PubMed Web of Science ®Google Scholar
• Goldring SR, Gravallese EM. (2000). Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 12:195–9.
   PubMed Web of Science ®Google Scholar
• Gu Y, Fan W, Yin G. (2014). The study of mechanisms of protective effect of Rg1 against Arthritis by inhibiting osteoclast differentiation and maturation in CIA Mice. Mediators Inflamm 2014:1–14.
   Web of Science ®Google Scholar
• Heymann D, Ory B, Gouin F, et al. (2004). Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 10:337–43.
   PubMed Web of Science ®Google Scholar
• Ishii M, Egen JG, Klauschen F, et al. (2009). Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458:524–8.
   PubMed Web of Science ®Google Scholar
• Karacivi M, Sumer Bolu B, Sanyal R, et al. (2017). Targeting to the bone: alendronate-directed combretastatin A-4 bearing antiangiogenic polymer-drug conjugates. Mol Pharm 14:1373–83.
   PubMed Web of Science ®Google Scholar
• Khan ZA, Tripathi R, Mishra B, et al. (2012). Methotrexate: a detailed review on drug delivery and clinical aspects. Expert Opin Drug Deliv 9:151–69.
   PubMed Web of Science ®Google Scholar
• Kim GW, Lee NR, Pi RH, et al. (2015). IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res 38:575–84.
   PubMed Web of Science ®Google Scholar
• Le Goff B, Soltner E, Charrier C, et al. (2009). A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther 11:R185.
   PubMed Web of Science ®Google Scholar
• Lee H, Bhang SH, Lee JH, et al. (2017). Tocilizumab-alendronate conjugate for treatment of rheumatoid arthritis. Bioconjug Chem 28:1084–92.
   PubMed Web of Science ®Google Scholar
• Li S, Shu B, Zhang Y, et al. (2014). Carboxyl terminus of Hsp70-interacting protein regulation of osteoclast formation in mice through promotion of tumor necrosis factor receptor-associated factor 6 protein degradation. Arthritis Rheumatol 66:1854–63.
   PubMed Web of Science ®Google Scholar
• Mount C, Featherstone J. (2005). Rheumatoid arthritis market. Nat Rev Drug Discov 4:11–12.
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Senior JR. (2006). Drug-related hepatotoxicity. N Engl J Med 354:731–9.
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Myoui A, Tomita T, et al. (2003). Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 48:2670–81.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Takayanagi H. (2011). Osteoclasts in arthritis and Th17 cell development. Int Immunopharmacol 11:543–8.
   PubMed Web of Science ®Google Scholar
• Pettit AR, Ji H, von Stechow D, et al. (2001). TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159:1689–99.
   PubMed Web of Science ®Google Scholar
• Redlich K, Hayer S, Ricci R, et al. (2002). Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110:1419–27.
   PubMed Web of Science ®Google Scholar
• Schett G. (2007). Erosive arthritis. Arthritis Res Ther 9 Suppl 1:S2.
   PubMed Web of Science ®Google Scholar
• Schett G, Gravallese E. (2012). Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8:656–64.
   PubMed Web of Science ®Google Scholar
• Shin JM, Kim S-H, Thambi T, et al. (2014). A hyaluronic acid-methotrexate conjugate for targeted therapy of rheumatoid arthritis. Chem Commun (Camb) 50:7632–5.
   PubMed Web of Science ®Google Scholar
• Song HP, Li X, Yu R, et al. (2015). Phenotypic characterization of type II collagen-induced arthritis in Wistar rats. Exp Ther Med 10:1483–88.
   PubMed Web of Science ®Google Scholar
• Stolina M, Adamu S, Ominsky M, et al. (2005). RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 20:1756–65.
   PubMed Web of Science ®Google Scholar
• Strand V, Cohen S, Schiff M, et al. (1999). Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159:2542–50.
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Ogasawara K, Hida S, et al. (2000). T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600–5.
   PubMed Web of Science ®Google Scholar
• Wang Y, Panasiuk A, Grainger DW, et al. (2011). Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures. Mol Pharm 8:1016–24.
   PubMed Web of Science ®Google Scholar
• Yang M, Ding J, Feng X, et al. (2017). Scavenger receptor-mediated targeted treatment of collagen-induced arthritis by dextran sulfate-methotrexate prodrug. Theranostics 7:97–105.
   PubMed Web of Science ®Google Scholar